Kintsugi, a startup developing AI to detect depression and anxiety from voice, is shutting down and open-sourcing its technology due to costly FDA regulatory hurdles. The company’s models analyzed brief speech samples and showed significantly higher depression detection rates than standard questionnaires in a health payer trial. The release aims to empower global research into voice biomarkers for mental healthcare.
Colorectal Cancer Alliance tackles rising young-onset cases with Never Too Young Taskforce and Project Cure CRC; LEAD FROM BEHIND wins Webby Award. Screening changes make 20M more eligible.
The Supreme Court allowed mifepristone to remain available via telehealth and mail while litigation continues. The FDA has also launched a six-month safety study of the abortion pill. Approximately 29% of U.S. abortions are now provided via telehealth.
India's drug regulator has mandated stronger safety warnings for doxycycline and carbimazole after a national review of adverse reaction reports. Doxycycline packages will now list potential mental health side effects such as anxiety and dizziness, while carbimazole will warn of a rare blood disorder.
A study using FAERS and MEPS data found that oral contraceptive side effects such as acne, migraine, anxiety, and depression vary by progestin type. Drospirenone-containing pills had higher reported rates of all four, while acne was also greater with levonorgestrel and norgestimate.
A study finds end-to-side anastomosis for Crohn’s disease may reduce endoscopic recurrence, while global data show early-onset colorectal cancer has the highest GI cancer burden in young adults, with rising incidence. Both studies highlight evolving challenges and treatment options in gastroenterology.
Two novel cervical cancer treatment approaches show progress: the CRAIN trial has completed dose-finding for tolinapant, an apoptosis inhibitor, while ICMR develops the SHetA2 pill for precancerous lesions.
More than 80% of U.S. physicians use AI in their work. AI is revealing new cardiac biomarkers and speeding drug discovery, with the healthcare AI market projected to reach $505.6 billion by 2033—but studies warn of bias and eroding critical thinking.
Two new studies show that genetic factors influence LDL cholesterol response to low-carb diets, while microbe-rich foods may improve insulin and cholesterol markers. The findings highlight personalized diet approaches.
Out-of-pocket maternal care costs have quadrupled in recent years, contributing to a medical mistrust movement. AI’s reputation as an unreliable force and medicine’s neglect of caring relationships further widen the trust gap.
Systematic review confirms hepatitis B birth dose is safe and effective; separate study finds childhood vaccination linked to significantly lower HBV coinfection in people with HIV.
Sheba Medical Center becomes first hospital outside the US to adopt OpenAI's healthcare AI models. Jerusalem launches FourWard medical innovation hub, and international health leaders visit Israeli labs to study medical innovation.
AI identified rectal cancer patients who benefit from adding irinotecan to chemoradiotherapy, cutting recurrence and death risk. Separate research finds most online AI-cancer information is low quality and too complex for patients.
The ERC Advanced Grant 2026 provides up to €2.5 million (plus possible additions) for established researchers pursuing frontier research in any discipline. Open until 27 Aug 2026, with no nationality or age restrictions.
Two catalytic strategies enable the enantioselective synthesis of chiral nitrogen-bridged heterocycles: a Brønsted acid-catalyzed transfer hydrogenation for 3-azabicyclo[3.1.1]heptanes, and a palladium-catalyzed cascade cyclization for bridged oxazole bicycles, both with broad scope and high stereoselectivity for drug discovery.
The European Commission granted marketing authorization to Sandoz for Bysumlog (insulin lispro) and Dazparda (insulin aspart), two biosimilar insulins developed by Gan & Lee Pharmaceuticals. A recent HHS analysis found most biosimilar markets become economically unviable after five competitors, prompting companies to diversify portfolios. Accord aims to bring 20 biosimilars to market by 2030.
The investigational ETVAX oral vaccine showed safety and immune responses in a Gambia-based phase 2b trial for enterotoxigenic E. coli. Efficacy reached 80.6% when excluding enteroparasitic pathogens. Results support progression to a phase 3 trial in high-burden settings.
GLP-1 receptor agonists are linked to a higher risk of smell and taste disturbances, while poison control calls involving semaglutide have soared since 2021. The drugs produce significant weight loss and are reshaping U.S. food demand, with roughly one in eight adults now taking them.
Two studies reveal how 3D genome architecture shapes early human development. One shows enhancers pre-connect with future target genes before activation, while the other finds germ cells restructure chromosomes before meiosis — a step critical for lab-grown sperm and eggs.
Sana Biotechnology stock gapped up over 13% on Tuesday after beating Q1 earnings estimates, continuing a Monday rally. Analysts reaffirmed a Moderate Buy consensus with a $9.50 target, as institutional ownership remains high at 88%.
